.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

OncLive® Scientific Interchange and Workshop Podcast Series: Management of HER2+ Breast Cancer

EP. 1: Examining the Unmet Needs in the Treatment of HER2-Positive Breast Cancer

June 8th 2021

In the first segment, Dr Gradishar and colleagues examine the unmet needs clinicians face despite recent advances in the treatment of patients with HER2-positive breast cancer.

EP. 2: Treating Early-Stage HER2-Positive Breast Cancer

June 8th 2021

Dr Gradishar and colleagues take an in-depth look at data from select clinical trials in the neoadjuvant and adjuvant settings for patients with HER2-positive breast cancer.

EP. 3: Advances in Metastatic HER2-Positive Breast Cancer

June 8th 2021

Dr Gradishar and colleagues highlight key clinical trials such as DESTINY-Breast01, HER2CLIMB, NALA, and SOPHIA in the setting of advanced HER2-positive breast cancer and discuss the practical considerations of these data.

EP. 4: Remaining Challenges in the Treatment of HER2-Positive Breast Cancer

July 28th 2021

In the first segment, Dr Mahtani and colleagues outline challenges and remaining unmet needs in the management of patients with HER2-positive breast cancer.

EP. 5: Managing Early-Stage HER2-Positive Breast Cancer

July 28th 2021

In the second segment, Dr Mahtani and colleagues discuss data from select clinical trials in the neoadjuvant and adjuvant settings for patients with HER2-positive breast cancer.

EP. 6: Updates in Advanced HER2-Positive Breast Cancer

July 28th 2021

Dr Mahtani and colleagues highlight key clinical trials such as DESTINY-Breast01, HER2CLIMB, NALA, and SOPHIA in the setting of advanced HER2-positive breast cancer and discuss the practical considerations of these data.

EP. 7: Challenges and Unmet Needs in the Treatment of HER2-Positive Breast Cancer

September 14th 2021

In the first segment, Dr Pegram and colleagues highlight some of the challenges and remaining unmet needs in the management of patients with HER2-positive breast cancer.

EP. 8: Management of Early-Stage HER2-Positive Breast Cancer

September 14th 2021

In the second segment, Dr Pegram and colleagues discuss the clinical implications of the data from select trials in the neoadjuvant and adjuvant settings for patients with HER2-positive breast cancer.

EP. 9: Updates and Advances in the Treatment of Metastatic HER2+ Breast Cancer

September 14th 2021

Dr Pegram and colleagues focus on key clinical trials such as DESTINY-Breast01, HER2CLIMB, NALA, and SOPHIA in the setting of advanced HER2-positive breast cancer and discuss the practical considerations of these data.